MS Care in Novel Coronavirus 19 Pandemic

Abstract

One hundred years after the influenza outbreak in 1918 coronavirus disease (COVID‑19) became a global health issue, which forces us to adapt our professional customs in the health care system. Our recent practice, since the 1990s, of processing experimental and observational evidences and time‑consuming methods of developing guidelines seem not to be efficient enough because of scarce evidence and rapidly spreading disease. According to formal announcements, until writing this letter, we had more than 95,000 COVID‑19 patients in Iran with a mortality rate of 6.3%.[1